Loading...
Please wait, while we are loading the content...
Similar Documents
Designing multi-epitope based peptide vaccine candidates against SARS-CoV-2 using immunoinformatics approach.
| Content Provider | Europe PMC |
|---|---|
| Author | Ysrafil, Ysrafil Sapiun, Zulfiayu Astuti, Indwiani Anasiru, Mohammad Anas Slamet, Nangsih Sulastri Hartati, Hartati Husain, Fadli Damiti, Sukmawati Ahmad |
| Copyright Year | 2022 |
| Abstract | Introduction: The current incidence of the novel coronavirus disease has shown only small reductions of cases and has become a major public health challenge. Development of effective vaccines against the virus is still being encouraged such as multi-epitope vaccines designed from the components of SARS-CoV-2 including its spike, nucleocapsid and ORF1a proteins. Since the addition of adjuvants including HABA protein and L7/L12 ribosomal are considered helpful to increase the effectiveness of the designed vaccine, we proposed to design multiepitope vaccines by two different adjuvants. Methods: We used the IEDB server to predict BCL and TCL epitopes that were characterized using online tools including VaxiJen, AllPred and IL-10 Prediction. The selected epitopes were further constructed into multiepitope vaccines. We also added two different adjuvants to the vaccine components in order to increase the effectiveness of the vaccines. The 3D-structured vaccines were built using trRosetta. They were further docked with different Toll-like-receptors (TLR 3, 4 and 8) and the entry receptor of SARS-CoV-2, ACE2 using ClusPro, PatchDock and refined by FireDock. All structures were visualized by USCF Chimera and PyMOL. Results: In this study, we succeeded in designing two different candidate vaccines by the addition of HABA protein and L7/L12 ribosomal as adjuvants. The two vaccines were almost equally good in terms of their physicochemical properties and characteristics. Likewise, their strong interactions with TLR3 4, 8 and ACE2 show the lowest energy level of both was estimated at more than -1,000. Interactions of vaccines with ACE2 and TLRs are essential for activation of immune responses and production of antibodies. Conclusion: The two designed and constructed multiepitope vaccine have good characteristics and may have the potential to activate humoral and cellular immune responses against SARS-CoV-2. Further research is worth considering to confirm the findings of this study. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9376164&blobtype=pdf |
| ISSN | 22285652 |
| Journal | BioImpacts : BI [Bioimpacts] |
| Volume Number | 12 |
| DOI | 10.34172/bi.2022.23769 |
| PubMed Central reference number | PMC9376164 |
| Issue Number | 4 |
| PubMed reference number | 35975206 |
| e-ISSN | 22285660 |
| Language | English |
| Publisher | Tabriz University of Medical Sciences (TUOMS Publishing Group) |
| Publisher Date | 2022-02-27 |
| Access Restriction | Open |
| Rights License | This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. © 2022 The Author(s). |
| Subject Keyword | SARS-COV-2 Immunoinformatics Multi-epitope vaccine candidate ACE2 |
| Content Type | Text |
| Resource Type | Article |
| Subject | Medicine Biochemistry, Genetics and Molecular Biology Pharmaceutical Science |
